Quick Answer
ATOSSA THERAPEUTICS, INC. reported R&D Expense of $21.18 million for fiscal year 2025.
ATOSSA THERAPEUTICS, INC. R&D Expense — Annual History
| Fiscal Year | R&D Expense | YoY Change |
|---|---|---|
| 2025 | $21.18M | +50.1% |
| 2024 | $14.12M | -18.6% |
| 2023 | $17.33M | +14.9% |
| 2022 | $15.08M | +63.8% |
| 2021 | $9.21M | +39.4% |
| 2020 | $6.61M | -0.6% |
| 2019 | $6.65M | +57.8% |
| 2018 | $4.21M | +80.8% |
| 2017 | $2.33M | +202.2% |
| 2016 | $770.4K | -67.3% |
| 2015 | $2.36M | +112.5% |
| 2014 | $1.11M | +0.5% |
| 2013 | $1.11M | -44.0% |
| 2012 | $1.97M | — |
Quarterly R&D Expense
| Quarter Ending | R&D Expense | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $5.37M | +57.4% | -2.4% |
| June 30, 2025 | $5.50M | +54.9% | +32.4% |
| March 31, 2025 | $4.16M | +10.9% | +21.8% |
| September 30, 2024 | $3.41M | -23.6% | -4.0% |
| June 30, 2024 | $3.55M | -4.1% | -5.2% |
| March 31, 2024 | $3.75M | +6.8% | -16.1% |
| September 30, 2023 | $4.47M | -13.4% | +20.6% |
| June 30, 2023 | $3.71M | +7.9% | +5.6% |
- ATOSSA THERAPEUTICS, INC. showed an increase of +50.1% in R&D Expense compared to the prior fiscal year.
- Over the 2012–2025 period, ATOSSA THERAPEUTICS, INC.’s r&d expense has grown by 973.2% (from $1.97 million to $21.18 million).
- The most recent figure is from ATOSSA THERAPEUTICS, INC.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 25, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: